AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
neostigmine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| acetylcholinesterase inhibitors | 1897 | 59-99-4 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike PHYSOSTIGMINE, does not cross the blood-brain barrier.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 60 | mg | O |
| 2 | mg | P |
| 0.40 | ml | None |
| 40 | mg | ointment |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 100 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 67 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.12 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 2 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 0.74 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 9.20 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 1.30 hours | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 1 % | Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | -2.710 | High | 1 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 2.018 | High | 1 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 0.230 | 10^-6 cm/s | High | 1 |
| dh-clint | Dog hepatocyte intrinsic clearance | 2.742 | uL/min/10^6 cells | High | 1 |
| dppb | Dog plasma protein binding (% unbound) | 96.180 | % | High | 1 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 95.050 | % | High | 1 |
| herg | hERG pIC50 | 4.363 | pIC50 | High | 1 |
| hh-clint | Human hepatocyte intrinsic clearance | 0.861 | uL/min/10^6 cells | High | 1 |
| hlm-clint | Human liver microsomal intrinsic clearance | 2.951 | uL/min/mg protein | High | 1 |
| hppb | Human plasma protein binding (% unbound) | 91.890 | % | High | 1 |
| kinase-safety-class | ACVR2A,ACVR2B,AKT2,AKT3,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GSK3B,ITK,JAK1,JAK2,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPK9,MAPKAPK2,MTOR,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CB,PIK3CG,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TTK,ULK1 | 49 | |||
| kinase-selectivity-class | ACVR2B,AXL,BRAF,CSF1R,DDR1,EPHB4,ERBB2,GRK2,MAPK7,PDK4,SIK2,STK33 | 12 | |||
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 0.975 | High | 1 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 7.962 | High | 1 | |
| mppb | Mouse plasma protein binding (% unbound) | 96.090 | High | 1 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 1.327 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 95.460 | % | High | 1 |
| rh-clint | Rat hepatocyte intrinsic clearance | 4.732 | uL/min/10^6 cells | High | 1 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 97.460 | % | High | 1 |
| rppb | Rat plasma protein binding (% unbound) | 95.560 | % | High | 1 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 907.821 | uM | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| May 31, 2013 | FDA | ECLAT PHARMS LLC |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Vascular encephalopathy | 96.73 | 31.12 | 17 | 2483 | 753 | 90625194 |
| Subileus | 91.37 | 31.12 | 21 | 2479 | 3623 | 90622324 |
| Schizencephaly | 73.78 | 31.12 | 12 | 2488 | 331 | 90625616 |
| Cerebral haemorrhage foetal | 73.61 | 31.12 | 12 | 2488 | 336 | 90625611 |
| Serotonin syndrome | 71.93 | 31.12 | 30 | 2470 | 37857 | 90588090 |
| Gastrointestinal sounds abnormal | 66.65 | 31.12 | 17 | 2483 | 4526 | 90621421 |
| Neuromuscular block prolonged | 66.08 | 31.12 | 12 | 2488 | 640 | 90625307 |
| Ileus | 63.81 | 31.12 | 22 | 2478 | 16524 | 90609423 |
| Negative pressure pulmonary oedema | 57.89 | 31.12 | 8 | 2492 | 69 | 90625878 |
| Stress cardiomyopathy | 56.36 | 31.12 | 19 | 2481 | 13336 | 90612611 |
| Dystonia | 55.82 | 31.12 | 20 | 2480 | 16799 | 90609148 |
| Abdominal tenderness | 54.56 | 31.12 | 17 | 2483 | 9307 | 90616640 |
| Hypotension | 54.11 | 31.12 | 55 | 2445 | 325342 | 90300605 |
| Faecaloma | 52.69 | 31.12 | 17 | 2483 | 10414 | 90615533 |
| Atrioventricular dissociation | 48.96 | 31.12 | 8 | 2492 | 227 | 90625720 |
| Apnoea | 46.15 | 31.12 | 15 | 2485 | 9399 | 90616548 |
| Procedural hypertension | 46.06 | 31.12 | 8 | 2492 | 330 | 90625617 |
| Cardiac arrest | 43.19 | 31.12 | 30 | 2470 | 104905 | 90521042 |
| Anaphylactic reaction | 43.17 | 31.12 | 28 | 2472 | 87496 | 90538451 |
| Pulmonary oedema | 41.18 | 31.12 | 24 | 2476 | 62056 | 90563891 |
| Brachial plexopathy | 40.99 | 31.12 | 7 | 2493 | 261 | 90625686 |
| Necrotising colitis | 40.52 | 31.12 | 9 | 2491 | 1329 | 90624618 |
| Dementia | 38.99 | 31.12 | 17 | 2483 | 23844 | 90602103 |
| Abdominal distension | 37.33 | 31.12 | 30 | 2470 | 130571 | 90495376 |
| White blood cell count increased | 36.85 | 31.12 | 23 | 2477 | 67218 | 90558729 |
| Bladder disorder | 36.45 | 31.12 | 13 | 2487 | 10759 | 90615188 |
| Myopia | 32.16 | 31.12 | 8 | 2492 | 1924 | 90624023 |
| Delayed recovery from anaesthesia | 31.59 | 31.12 | 7 | 2493 | 1023 | 90624924 |
| Chorea | 31.46 | 31.12 | 8 | 2492 | 2102 | 90623845 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Serotonin syndrome | 118.80 | 34.39 | 41 | 1380 | 25804 | 42594110 |
| Bradycardia | 108.63 | 34.39 | 54 | 1367 | 85430 | 42534484 |
| Cardiac arrest | 88.01 | 34.39 | 51 | 1370 | 109269 | 42510645 |
| Drug interaction | 62.39 | 34.39 | 59 | 1362 | 266940 | 42352974 |
| Metabolic acidosis | 51.95 | 34.39 | 28 | 1393 | 51830 | 42568084 |
| Pseudomonal sepsis | 50.52 | 34.39 | 14 | 1407 | 4235 | 42615679 |
| Renal ischaemia | 47.25 | 34.39 | 11 | 1410 | 1659 | 42618255 |
| Accelerated idioventricular rhythm | 41.90 | 34.39 | 7 | 1414 | 188 | 42619726 |
| Appendicitis perforated | 39.69 | 34.39 | 10 | 1411 | 2096 | 42617818 |
| Hyperthermia malignant | 37.38 | 34.39 | 10 | 1411 | 2648 | 42617266 |
| Atrioventricular block second degree | 37.22 | 34.39 | 11 | 1410 | 4176 | 42615738 |
| Acute pulmonary oedema | 36.85 | 34.39 | 13 | 1408 | 8638 | 42611276 |
| Angle closure glaucoma | 34.98 | 34.39 | 8 | 1413 | 1114 | 42618800 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Serotonin syndrome | 140.16 | 27.04 | 59 | 3878 | 59094 | 110526268 |
| Bradycardia | 118.80 | 27.04 | 72 | 3865 | 155445 | 110429917 |
| Cardiac arrest | 110.42 | 27.04 | 75 | 3862 | 196678 | 110388684 |
| Vascular encephalopathy | 91.22 | 27.04 | 17 | 3920 | 807 | 110584555 |
| Subileus | 74.16 | 27.04 | 21 | 3916 | 6416 | 110578946 |
| Pulmonary oedema | 70.14 | 27.04 | 44 | 3893 | 100615 | 110484747 |
| Neuromuscular block prolonged | 66.62 | 27.04 | 14 | 3923 | 1233 | 110584129 |
| Drug interaction | 63.11 | 27.04 | 83 | 3854 | 500100 | 110085262 |
| Gastrointestinal sounds abnormal | 57.61 | 27.04 | 17 | 3920 | 6001 | 110579361 |
| Ileus | 57.55 | 27.04 | 26 | 3911 | 30703 | 110554659 |
| Hypotension | 57.11 | 27.04 | 81 | 3856 | 523768 | 110061594 |
| Stress cardiomyopathy | 55.63 | 27.04 | 21 | 3916 | 15785 | 110569577 |
| Laryngospasm | 52.74 | 27.04 | 15 | 3922 | 4653 | 110580709 |
| Dystonia | 52.05 | 27.04 | 23 | 3914 | 25782 | 110559580 |
| Tachycardia | 51.34 | 27.04 | 51 | 3886 | 226594 | 110358768 |
| Apnoea | 51.20 | 27.04 | 19 | 3918 | 13620 | 110571742 |
| Abdominal tenderness | 45.47 | 27.04 | 17 | 3920 | 12440 | 110572922 |
| White blood cell count increased | 45.10 | 27.04 | 33 | 3904 | 96809 | 110488553 |
| Negative pressure pulmonary oedema | 44.05 | 27.04 | 9 | 3928 | 690 | 110584672 |
| Procedural hypertension | 43.76 | 27.04 | 8 | 3929 | 341 | 110585021 |
| Delayed recovery from anaesthesia | 43.41 | 27.04 | 11 | 3926 | 2204 | 110583158 |
| Renal ischaemia | 42.89 | 27.04 | 11 | 3926 | 2312 | 110583050 |
| Atrioventricular dissociation | 42.79 | 27.04 | 8 | 3929 | 386 | 110584976 |
| Hyperthermia malignant | 41.67 | 27.04 | 12 | 3925 | 3888 | 110581474 |
| Faecaloma | 39.06 | 27.04 | 16 | 3921 | 14892 | 110570470 |
| Accelerated idioventricular rhythm | 38.60 | 27.04 | 7 | 3930 | 285 | 110585077 |
| Brachial plexopathy | 38.28 | 27.04 | 7 | 3930 | 299 | 110585063 |
| Atrioventricular block second degree | 36.69 | 27.04 | 13 | 3924 | 8168 | 110577194 |
| Anaphylactic reaction | 36.11 | 27.04 | 31 | 3906 | 114269 | 110471093 |
| Necrotising colitis | 35.75 | 27.04 | 9 | 3928 | 1756 | 110583606 |
| Atrioventricular block complete | 34.48 | 27.04 | 16 | 3921 | 20066 | 110565296 |
| Acute pulmonary oedema | 33.79 | 27.04 | 15 | 3922 | 16981 | 110568381 |
| Appendicitis perforated | 33.57 | 27.04 | 10 | 3927 | 3642 | 110581720 |
| Abdominal distension | 33.47 | 27.04 | 36 | 3901 | 175067 | 110410295 |
| Metabolic acidosis | 33.45 | 27.04 | 28 | 3909 | 99716 | 110485646 |
| Cholinergic syndrome | 33.08 | 27.04 | 8 | 3929 | 1324 | 110584038 |
| Bladder disorder | 32.79 | 27.04 | 13 | 3924 | 11124 | 110574238 |
| Pseudomonal sepsis | 31.76 | 27.04 | 12 | 3925 | 9034 | 110576328 |
| Dementia | 30.28 | 27.04 | 17 | 3920 | 31656 | 110553706 |
| Post procedural complication | 30.18 | 27.04 | 16 | 3921 | 26642 | 110558720 |
| Intestinal pseudo-obstruction | 30.03 | 27.04 | 9 | 3928 | 3347 | 110582015 |
| Non-cardiogenic pulmonary oedema | 29.92 | 27.04 | 8 | 3929 | 1976 | 110583386 |
| Angle closure glaucoma | 29.66 | 27.04 | 9 | 3928 | 3490 | 110581872 |
| Myopia | 28.85 | 27.04 | 8 | 3929 | 2263 | 110583099 |
| Respiratory failure | 27.45 | 27.04 | 36 | 3901 | 215296 | 110370066 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | N07AA01 | NERVOUS SYSTEM OTHER NERVOUS SYSTEM DRUGS PARASYMPATHOMIMETICS Anticholinesterases |
| ATC | N07AA51 | NERVOUS SYSTEM OTHER NERVOUS SYSTEM DRUGS PARASYMPATHOMIMETICS Anticholinesterases |
| ATC | S01EB06 | SENSORY ORGANS OPHTHALMOLOGICALS ANTIGLAUCOMA PREPARATIONS AND MIOTICS Parasympathomimetics |
| FDA MoA | N0000000177 | Cholinesterase Inhibitors |
| MeSH PA | D002800 | Cholinesterase Inhibitors |
| MeSH PA | D004791 | Enzyme Inhibitors |
| MeSH PA | D010277 | Parasympathomimetics |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D018678 | Cholinergic Agents |
| FDA EPC | N0000175723 | Cholinesterase Inhibitor |
| CHEBI has role | CHEBI:35480 | analgesic |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:38462 | EC 3.1.1.7 (acetylcholinesterase) inhibitor |
| CHEBI has role | CHEBI:39456 | antiglaucoma drug |
| CHEBI has role | CHEBI:55324 | gastrointestinal drug |
| CHEBI has role | CHEBI:74518 | anti-obesity agent |
| CHEBI has role | CHEBI:74530 | antidote to curare poisoning |
| CHEBI has role | CHEBI:231911 | renoprotective agent |
| CHEBI has role | CHEBI:37733 | EC 3.1.1.8 (cholinesterase) inhibitor |
Related Drugs by ATC class:
N07AA Anticholinesterases 3 drugs
S01EB Parasympathomimetics 9 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Myasthenia gravis | indication | 91637004 | DOID:437 |
| Reversal of neuromuscular blockade | indication | 241703000 | |
| Retention of urine | indication | 267064002 | |
| Urinary tract obstruction | contraindication | 7163005 | DOID:5200 |
| Peptic ulcer | contraindication | 13200003 | DOID:750 |
| Increased gastric tonus | contraindication | 18644006 | |
| Hyperthyroidism | contraindication | 34486009 | DOID:7998 |
| Conduction disorder of the heart | contraindication | 44808001 | |
| Peritonitis | contraindication | 48661000 | |
| Sinus bradycardia | contraindication | 49710005 | |
| Coronary occlusion | contraindication | 63739005 | |
| Gastrointestinal obstruction | contraindication | 126765001 | |
| Seizure disorder | contraindication | 128613002 | |
| Asthma | contraindication | 195967001 | DOID:2841 |
| Macrocolon | contraindication | 367495003 | |
| Gastrointestinal hypomotility | contraindication | 421807004 | |
| Increased Bronchial Secretions | contraindication | ||
| Colonic Necrosis | contraindication |
🐶 Veterinary Drug Use
| Species | Use | Relation |
|---|---|---|
| Cattle | Rumen atony | Indication |
| Cattle | Initiating peristalsis which causes evacuation of the bowel | Indication |
| Cattle | Emptying the urinary bladder | Indication |
| Cattle | Stimulating skeletal muscle contractions | Indication |
| Cattle | Antagonizes the effect of curare | Indication |
| Horses | Rumen atony | Indication |
| Horses | Initiating peristalsis which causes evacuation of the bowel | Indication |
| Horses | Emptying the urinary bladder | Indication |
| Horses | Stimulating skeletal muscle contractions | Indication |
| Horses | Antagonizes the effect of curare | Indication |
| Sheep | Rumen atony | Indication |
| Sheep | Initiating peristalsis which causes evacuation of the bowel | Indication |
| Sheep | Emptying the urinary bladder | Indication |
| Sheep | Stimulating skeletal muscle contractions | Indication |
| Sheep | Antagonizes the effect of curare | Indication |
| Swine | Rumen atony | Indication |
| Swine | Initiating peristalsis which causes evacuation of the bowel | Indication |
| Swine | Emptying the urinary bladder | Indication |
| Swine | Stimulating skeletal muscle contractions | Indication |
| Swine | Antagonizes the effect of curare | Indication |
🐶 Veterinary products
| Product | Applicant | Ingredients |
|---|---|---|
| Stiglyn 1:500 | Intervet Inc. | 1 |
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Acetylcholinesterase | Enzyme | INHIBITOR | IC50 | 7.59 | WOMBAT-PK | CHEMBL | |||
| Cholinesterase | Enzyme | IC50 | 7.22 | CHEMBL | |||||
| Acetylcholinesterase | Enzyme | IC50 | 8.34 | CHEMBL | |||||
| Acetylcholinesterase | Enzyme | IC50 | 7.46 | CHEMBL | |||||
| Acetylcholinesterase | Enzyme | Ki | 6 | CHEMBL | |||||
| Cholinesterase | Enzyme | IC50 | 7.15 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4019856 | VUID |
| N0000147942 | NUI |
| D00995 | KEGG_DRUG |
| 51-60-5 | SECONDARY_CAS_RN |
| 4017784 | VANDF |
| 4017785 | VANDF |
| 4019856 | VANDF |
| C0027679 | UMLSCUI |
| CHEMBL278020 | ChEMBL_ID |
| DB01400 | DRUGBANK_ID |
| CHEMBL211471 | ChEMBL_ID |
| CHEMBL54126 | ChEMBL_ID |
| D009388 | MESH_DESCRIPTOR_UI |
| 4456 | PUBCHEM_CID |
| 8993 | IUPHAR_LIGAND_ID |
| 114-80-7 | SECONDARY_CAS_RN |
| 3982TWQ96G | UNII |
| 262500 | RXNORM |
| 3968 | MMSL |
| 5165 | MMSL |
| 5166 | MMSL |
| 72417 | MMSL |
| 9863 | MMSL |
| d00313 | MMSL |
| 001703 | NDDF |
| 001704 | NDDF |
| 001705 | NDDF |
| 373346001 | SNOMEDCT_US |
| 387294009 | SNOMEDCT_US |
| 80024007 | SNOMEDCT_US |
| 87151005 | SNOMEDCT_US |
| CHEBI:7514 | CHEBI |
| 401 | INN_ID |
| 3982TWQ96G | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| NEOSTIGMINE METHYLSULFATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0548-9601 | INJECTION | 0.50 mg | INTRAVENOUS | ANDA | 16 sections |
| NEOSTIGMINE METHYLSULFATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0548-9602 | INJECTION | 1 mg | INTRAVENOUS | ANDA | 16 sections |
| Neostigmine Methylsulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-6149 | INJECTION | 1 mg | INTRAVENOUS | ANDA | 24 sections |
| Neostigmine Methylsulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-6150 | INJECTION | 0.50 mg | INTRAVENOUS | ANDA | 24 sections |
| Neostigmine Methylsulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-6264 | INJECTION | 0.50 mg | INTRAVENOUS | ANDA | 24 sections |
| Neostigmine Methylsulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-6265 | INJECTION | 1 mg | INTRAVENOUS | ANDA | 24 sections |
| Neostigmine Methylsulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-6277 | INJECTION | 1 mg | INTRAVENOUS | ANDA | 24 sections |
| NEOSTIGMINE METHYLSULFATE | Human Prescription Drug Label | 1 | 14445-413 | INJECTION | 0.50 mg | INTRAVENOUS | ANDA | 24 sections |
| NEOSTIGMINE METHYLSULFATE | Human Prescription Drug Label | 1 | 14445-414 | INJECTION | 1 mg | INTRAVENOUS | ANDA | 24 sections |
| Neostigmine Methylsulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 23155-517 | INJECTION | 0.50 mg | INTRAVENOUS | ANDA | 23 sections |
| Neostigmine Methylsulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 23155-518 | INJECTION | 1 mg | INTRAVENOUS | ANDA | 23 sections |
| Neostigmine Methylsulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 25021-610 | INJECTION, SOLUTION | 0.50 mg | INTRAVENOUS | ANDA | 28 sections |
| Neostigmine Methylsulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 25021-611 | INJECTION, SOLUTION | 1 mg | INTRAVENOUS | ANDA | 28 sections |
| neostigmine methylsulfate | Human Prescription Drug Label | 1 | 31722-994 | INJECTION | 0.50 mg | INTRAVENOUS | ANDA | 24 sections |
| neostigmine methylsulfate | Human Prescription Drug Label | 1 | 31722-995 | INJECTION | 1 mg | INTRAVENOUS | ANDA | 24 sections |
| NEOSTIGMINE METHYLSULFATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42023-188 | INJECTION | 0.50 mg | INTRAVENOUS | ANDA | 23 sections |
| NEOSTIGMINE METHYLSULFATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42023-189 | INJECTION | 1 mg | INTRAVENOUS | ANDA | 23 sections |
| PREVDUO | Human Prescription Drug Label | 2 | 42023-269 | INJECTION | 1 mg | INTRAVENOUS | NDA | 25 sections |
| Neostigmine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43598-528 | INJECTION | 0.50 mg | INTRAVENOUS | ANDA | 24 sections |
| Neostigmine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43598-529 | INJECTION | 1 mg | INTRAVENOUS | ANDA | 24 sections |
| Neostigmine Methylsulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43598-945 | INJECTION, SOLUTION | 1 mg | INTRAVENOUS | ANDA | 26 sections |
| NEOSTIGMINE METHYLSULFATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-4532 | INJECTION | 1 mg | INTRAVENOUS | ANDA | 17 sections |
| Neostigmine methylsulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-5197 | INJECTION | 0.50 mg | INTRAVENOUS | ANDA | 25 sections |
| NEOSTIGMINE METHYLSULFATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51662-1557 | INJECTION | 1 mg | INTRAVENOUS | ANDA | 16 sections |
| Bloxiverz | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51754-1200 | INJECTION | 1 mg | INTRAVENOUS | NDA | 25 sections |
| Bloxiverz | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51754-1210 | INJECTION | 0.50 mg | INTRAVENOUS | NDA | 25 sections |
| Bloxiverz | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51754-1220 | INJECTION | 1 mg | INTRAVENOUS | NDA | 25 sections |
| Bloxiverz | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51754-1240 | INJECTION | 1 mg | INTRAVENOUS | NDA | 26 sections |
| Bloxiverz | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51754-1240 | INJECTION | 1 mg | INTRAVENOUS | NDA | 26 sections |
| NEOSTIGMINE METHYLSULFATE | Human Prescription Drug Label | 1 | 55150-348 | INJECTION | 0.50 mg | INTRAVENOUS | ANDA | 24 sections |